HIV patients may ditch daily pills for monthly shots in landmark trial

NCT ID NCT02951052

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 18 times

Summary

This study tested whether adults with HIV whose virus is already suppressed by daily pills can switch to a monthly injection of two long-acting drugs (cabotegravir and rilpivirine) and keep the virus under control. About 618 participants were randomly assigned to either stay on their daily oral regimen or switch to the monthly shots. The goal was to see if the shots work as well as daily pills at maintaining viral suppression over 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Birmingham, Alabama, 35294, United States
GSK Investigational Site

Phoenix, Arizona, 85015, United States
GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

Long Beach, California, 90813, United States
GSK Investigational Site

Los Angeles, California, 90036, United States
GSK Investigational Site

Los Angeles, California, 90069, United States
GSK Investigational Site

Palm Springs, California, 92264, United States
GSK Investigational Site

San Francisco, California, 94109, United States
GSK Investigational Site

San Francisco, California, 94110, United States
GSK Investigational Site

Denver, Colorado, 80246, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20007, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20009, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20037, United States
GSK Investigational Site

Fort Lauderdale, Florida, 33316, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Sarasota, Florida, 34237, United States
GSK Investigational Site

Vero Beach, Florida, 32960, United States
GSK Investigational Site

Macon, Georgia, 31201, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Boston, Massachusetts, 02129, United States
GSK Investigational Site

Detroit, Michigan, 48202, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

Omaha, Nebraska, 68198, United States
GSK Investigational Site

Buffalo, New York, 14201, United States
GSK Investigational Site

New York, New York, 10016, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

Chapel Hill, North Carolina, 27599-7064, United States
GSK Investigational Site

Charlotte, North Carolina, 28209, United States
GSK Investigational Site

Cincinnati, Ohio, 45267-0405, United States
GSK Investigational Site

Allentown, Pennsylvania, 18102, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15212, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Houston, Texas, 77098, United States
GSK Investigational Site

Annandale, Virginia, 22003, United States
GSK Investigational Site

Lynchburg, Virginia, 24501, United States
GSK Investigational Site

Buenos Aires, 1141, Argentina
GSK Investigational Site

Buenos Aires, 1427, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1405CKC, Argentina
GSK Investigational Site

Rosario, 2000, Argentina
GSK Investigational Site

Darlinghurst, New South Wales, 2010, Australia
GSK Investigational Site

Sydney, New South Wales, 2010, Australia
GSK Investigational Site

Prahran, Victoria, 3181, Australia
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 1K2, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4E9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Québec, Quebec, G1V 4G2, Canada
GSK Investigational Site

Regina, Saskatchewan, S4P 0W5, Canada
GSK Investigational Site

Montpellier, 34295, France
GSK Investigational Site

Paris, 75018, France
GSK Investigational Site

Paris, 75475, France
GSK Investigational Site

Paris, 75571, France
GSK Investigational Site

Paris, 75651, France
GSK Investigational Site

Saint-Denis, 93205, France
GSK Investigational Site

Toulouse, 31059, France
GSK Investigational Site

Tourcoing, 59208, France
GSK Investigational Site

Berlin, 10439, Germany
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Bonn, 53127, Germany
GSK Investigational Site

Essen, 45122, Germany
GSK Investigational Site

Frankfurt, 60590, Germany
GSK Investigational Site

Frankfurt, 60596, Germany
GSK Investigational Site

Hamburg, 20146, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

Hanover, 30625, Germany
GSK Investigational Site

München, 80335, Germany
GSK Investigational Site

Brescia, 25123, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Guadalajara, 44280, Mexico
GSK Investigational Site

Kazan', 420061, Russia
GSK Investigational Site

Kemerovo, 650056, Russia
GSK Investigational Site

Krasnodar, 350015, Russia
GSK Investigational Site

Lipetsk, 398043, Russia
GSK Investigational Site

Moscow, 105275, Russia
GSK Investigational Site

Oryol, 302040, Russia
GSK Investigational Site

Saint Petersburg, 190103, Russia
GSK Investigational Site

Saint Petersburg, 193167, Russia
GSK Investigational Site

Saint Petersburg, 196645, Russia
GSK Investigational Site

Saratov, 410009, Russia
GSK Investigational Site

Smolensk, 214006, Russia
GSK Investigational Site

Toliyatti, 445846, Russia
GSK Investigational Site

Yekaterinburg, 620102, Russia
GSK Investigational Site

Bloemfontein, 9301, South Africa
GSK Investigational Site

Cape Town, 7925, South Africa
GSK Investigational Site

Durban, 4001, South Africa
GSK Investigational Site

Durban, 4052, South Africa
GSK Investigational Site

Johannesburg, 2113, South Africa
GSK Investigational Site

Middelburg, 1055, South Africa
GSK Investigational Site

Pretorai, 0087, South Africa
GSK Investigational Site

Winnie Mandela, 9400, South Africa
GSK Investigational Site

Daegu, 41944, South Korea
GSK Investigational Site

Daejeon, 35015, South Korea
GSK Investigational Site

Pusan, 49241, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Badalona, 08916, Spain
GSK Investigational Site

Barcelona, 08003, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Elche Alicante, 03203, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Santiago de Compostela, 15706, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Valencia, 46014, Spain
GSK Investigational Site

Vigo Pontevedra, 36312, Spain
GSK Investigational Site

Gothenburg, SE-416 85, Sweden
GSK Investigational Site

Stockholm, SE-118 83, Sweden
GSK Investigational Site

Stockholm, SE-14186, Sweden

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS INFECTION, HUMAN IMMUNODEFICIENCY VIRUS